Skip to content

OxSonics® Wins European Healthtech Investment Forum Competition

OxSonics® Wins European Healthtech Investment Forum Competition

Oxford, UK – 13th March 2019 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer presented at the 2019 European Healthtech Investment Forum in Helsinki.

OxSonics was one of 40 companies selected to present at the meeting out of an original 136 companies that applied. An expert panel of reviewers selected OxSonics as 1 of 10 winning companies at the event based on the quality of the investment presentation and proposition given at the meeting. Each of the 10 winning companies was awarded a finalist position in the 13th European Venture Contest to be held in Dusseldorf in December 2019.

Commenting on the win, Colin Story, CEO wrote: “We’re very pleased to be one of ten companies out of an original 136 to win a finalist position in this European-wide competition. All entrants are judged on the case for future investment and how this case is presented to the expert judging panels. The judges were quick to identify with the major clinical and commercial opportunity that our drug delivery platform, SonoTran®, offers. This further validation of the opportunity is testament to the hard work and dedication offered by everyone at OxSonics and many of our very supportive collaborators.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: